Browse NIPA1

Summary
SymbolNIPA1
Namenon imprinted in Prader-Willi/Angelman syndrome 1
Aliases MGC35570; SPG6; spastic paraplegia 6 (autosomal dominant); FSP3; non-imprinted in Prader-Willi/Angelman synd ......
Chromosomal Location15q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Multi-pass membrane protein Early endosome Note=Recruited to the cell membrane in response to low extracellular magnesium.
Domain PF05653 Magnesium transporter NIPA
Function

Acts as a Mg(2+) transporter. Can also transport other divalent cations such as Fe(2+), Sr(2+), Ba(2+), Mn(2+) and Co(2+) but to a much less extent than Mg(2+) (By similarity).

> Gene Ontology
 
Biological Process GO:0015693 magnesium ion transport
GO:0070838 divalent metal ion transport
GO:0072511 divalent inorganic cation transport
GO:1903830 magnesium ion transmembrane transport
Molecular Function GO:0015095 magnesium ion transmembrane transporter activity
GO:0046873 metal ion transmembrane transporter activity
GO:0072509 divalent inorganic cation transmembrane transporter activity
Cellular Component GO:0005769 early endosome
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-5223345: Miscellaneous transport and binding events
R-HSA-382551: Transmembrane transport of small molecules
Summary
SymbolNIPA1
Namenon imprinted in Prader-Willi/Angelman syndrome 1
Aliases MGC35570; SPG6; spastic paraplegia 6 (autosomal dominant); FSP3; non-imprinted in Prader-Willi/Angelman synd ......
Chromosomal Location15q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NIPA1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolNIPA1
Namenon imprinted in Prader-Willi/Angelman syndrome 1
Aliases MGC35570; SPG6; spastic paraplegia 6 (autosomal dominant); FSP3; non-imprinted in Prader-Willi/Angelman synd ......
Chromosomal Location15q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NIPA1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolNIPA1
Namenon imprinted in Prader-Willi/Angelman syndrome 1
Aliases MGC35570; SPG6; spastic paraplegia 6 (autosomal dominant); FSP3; non-imprinted in Prader-Willi/Angelman synd ......
Chromosomal Location15q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NIPA1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.8120.0467
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.5790.24
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2640.765
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0760.79
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.4370.694
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.3730.804
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4410.264
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.9240.521
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.020.989
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2140.819
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.3060.816
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0390.74
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NIPA1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolNIPA1
Namenon imprinted in Prader-Willi/Angelman syndrome 1
Aliases MGC35570; SPG6; spastic paraplegia 6 (autosomal dominant); FSP3; non-imprinted in Prader-Willi/Angelman synd ......
Chromosomal Location15q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NIPA1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNIPA1
Namenon imprinted in Prader-Willi/Angelman syndrome 1
Aliases MGC35570; SPG6; spastic paraplegia 6 (autosomal dominant); FSP3; non-imprinted in Prader-Willi/Angelman synd ......
Chromosomal Location15q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NIPA1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NIPA1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNIPA1
Namenon imprinted in Prader-Willi/Angelman syndrome 1
Aliases MGC35570; SPG6; spastic paraplegia 6 (autosomal dominant); FSP3; non-imprinted in Prader-Willi/Angelman synd ......
Chromosomal Location15q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NIPA1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNIPA1
Namenon imprinted in Prader-Willi/Angelman syndrome 1
Aliases MGC35570; SPG6; spastic paraplegia 6 (autosomal dominant); FSP3; non-imprinted in Prader-Willi/Angelman synd ......
Chromosomal Location15q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NIPA1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNIPA1
Namenon imprinted in Prader-Willi/Angelman syndrome 1
Aliases MGC35570; SPG6; spastic paraplegia 6 (autosomal dominant); FSP3; non-imprinted in Prader-Willi/Angelman synd ......
Chromosomal Location15q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NIPA1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNIPA1
Namenon imprinted in Prader-Willi/Angelman syndrome 1
Aliases MGC35570; SPG6; spastic paraplegia 6 (autosomal dominant); FSP3; non-imprinted in Prader-Willi/Angelman synd ......
Chromosomal Location15q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NIPA1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.